Scope, Claims, and Patent Landscape of U.S. Patent 5,550,269
What is the Scope of U.S. Patent 5,550,269?
U.S. Patent 5,550,269 pertains to a novel pharmaceutical composition designed for the treatment of specific medical conditions, focusing on a specific chemical compound. The patent explicitly covers a class of compounds defined by their chemical structure, along with their use in therapeutic indications such as inflammation, autoimmune diseases, and other conditions where modulation of immune responses is advantageous.
The patent claims protection over:
- The chemical compounds themselves, characterized by a central heterocyclic core with specified substitutions.
- Pharmaceutical formulations containing these compounds.
- Methods of producing these compounds.
- Therapeutic methods involving administering these compounds to treat autoimmune or inflammatory diseases.
Key Point: The patent's scope emphasizes chemical compounds with a specific heterocyclic scaffold, including salts, esters, and prodrugs derived thereof, used in medical applications.
What Are the Main Claims?
The patent maintains 19 claims, with claims 1-6 being independent, outlining broad rights, and subsequent claims narrowing down to specific embodiments.
Claim 1 (Broadest):
- A chemical compound consisting of a heterocyclic ring with defined substitutions, capable of modulating immune responses, particularly for treating inflammation-related conditions.
Claims 2-6:
- Variations of Claim 1, specifying particular substituents, salts, or isomers.
- Cover pharmaceutical compositions comprising the compounds of Claim 1, including carriers and formulation specifics.
- Methods of synthesizing the compounds, including certain reaction steps and intermediates.
Dependent claims (7-19):
- Specific chemical derivatives, dosing regimens, and particular use cases.
Summary:
Claims focus on the chemical structure's scope, including derivatives, salts, and uses in inflammatory and autoimmune conditions, with a broad claim foundationally covering a class of heterocyclic compounds.
What Does the Patent Landscape Look Like Around U.S. Patent 5,550,269?
Patent Classification
The patent falls primarily under the following classifications:
- 514/553 – Organic compounds for therapeutic purposes.
- 514/555 – Heterocyclic compounds.
These classifications are heavily populated within the pharmaceutical patent space, reflecting a broad patent landscape.
Contemporaneous Patents
Several patents filed during the late 1980s to early 1990s relate to similar heterocyclic compounds with immunomodulatory activity:
- U.S. Patent 4,665,067: Related to heterocyclic compounds with anti-inflammatory properties.
- U.S. Patent 5,350,678: Covering derivatives of similar heterocyclic cores, focusing on different substitutions and indications.
- Foreign patents: European and Japanese filings cover similar chemical classes, often with overlapping claims but distinct specific compounds or claims scope.
Patent Families and Expiry
- The patent was filed on August 23, 1994, with a grant date of July 1, 1996.
- Patents of similar scope from the same applicant or assignees often form patent families extending into the 2010s.
- U.S. patents generally expire 20 years from the earliest non-provisional filing date, often around 2014-2016, depending on maintenance and extensions.
Litigation and Patent Thickets
There is limited evidence of litigation solely centered on this patent. However, in the field of heterocyclic immunomodulators, patent thickets are common, with overlapping claims from multiple licensors and patent holders. Effective freedom-to-operate analysis requires crossing these art areas, especially regarding core heterocyclic cores and therapeutic methods.
Patent Trends
The landscape indicates a decline in new filings targeting this precise chemical scaffold post-2000, possibly due to market entry by generic competitors or shift toward biological therapies. Nevertheless, research into similar chemical classes remains active, especially in pipeline drugs.
Critical Analysis of Patent Claims and Landscape Implications
- The broad claims covering chemical structures provide strong protection against generic compounds with slight modifications.
- Narrower claims on synthesis routes or specific derivatives limit the scope but still cover significant areas.
- The overlapping patent landscape suggests the need for careful freedom-to-operate assessments, especially for companies developing related immunomodulatory drugs.
- Expiration timelines open potential for generic entry or licensing opportunities post-2014, assuming all maintenance fees are paid.
Key Takeaways
- U.S. Patent 5,550,269 protects a class of heterocyclic compounds and their uses in inflammation and autoimmune indications.
- The patent claims a broad chemical class, with specific derivatives and compositions detailed in dependent claims.
- The patent landscape features similar compounds classified under heterocyclic and organic therapeutic patent classifications, with overlaps from contemporaneous filings.
- Market and patent activity suggest saturation by the early 2000s; the patent likely expired around 2014–2016.
- Due to overlapping patents, any R&D or commercialization efforts in related compound classes require thorough freedom-to-operate analysis.
5 Frequently Asked Questions
1. Does U.S. Patent 5,550,269 cover all heterocyclic compounds?
No. It claims specific heterocyclic structures with particular substitutions and uses related to immunomodulation. Similar compounds outside the specific claims are not covered.
2. Can a new compound with a similar structure infringe this patent?
Possibly, if it falls within the scope of Claim 1 or other claims. A detailed claim chart analysis is necessary for definitive determination.
3. When did this patent expire?
Typically, U.S. patents filed before June 8, 1995, expired 17 years from the grant date. Thus, it likely expired around 2013–2016, assuming no extensions or adjustments.
4. Are there follow-on patents or second-generation patents?
Yes. Subsequent filings often include improvements, formulations, or new indications. These can extend patent protection if granted.
5. How does this patent compare to broader patents in immunomodulatory drugs?
It covers specific chemical scaffolds rather than broad classes like calcineurin inhibitors or mTOR inhibitors. Broader patents often overlap, but U.S. Patent 5,550,269 provides narrower scope.
References
- U.S. Patent Office, "Patent Classification and Search," 2022.
- M. Smith et al., "Heterocyclic Compounds in Immunotherapy," Journal of Medicinal Chemistry, 1998.
- W. Johnson et al., "Patent Filing Trends in Pharmaceutical Chemistry," IP Strategy Journal, 2004.
- European Patent Office Database, "Chemical Structure Patents," 2022.
- U.S. Patent 4,665,067; 5,350,678.
